Immunic reports positive interim data from phase 2 calliper trial of vidofludimus calcium in progressive multiple sclerosis

– 24-week data from first half of patients shows improvements in biomarker nfl, consistent throughout the overall progressive multiple sclerosis population as well as all subtypes  – – nfl effect in non-active subpopulation reinforces vidofludimus calcium's neuroprotective potential – – brain volume data of the full 467 calliper patient cohort expected in april 2025 – – phase 3 ensure program in relapsing multiple sclerosis ongoing – – conference call and webcast to be held tomorrow, october 10, 2023 at 8:00 am et – new york , oct. 9, 2023 /prnewswire/ -- immunic, inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive interim data from its phase 2 calliper trial of nuclear receptor related 1 (nurr1) activator, vidofludimus calcium (imu-838), in patients with progressive multiple sclerosis (pms). the company believes that this data shows biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential.
IMUX Ratings Summary
IMUX Quant Ranking